OSUR
OraSure Technologies, Inc.
Price Chart
Latest Quote
$4.16
-0.09 (-2.12%)
Current Price
| Previous Close | $4.25 |
| Open | $4.23 |
| Day High | $4.31 |
| Day Low | $4.09 |
| Volume | 610,552 |
Stock Information
| Shares Outstanding | 68.85M |
| Total Debt | $12.66M |
| Cash Equivalents | $176.96M |
| Revenue | $113.02M |
| Net Income | $-75.07M |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $286.41M |
| EPS (TTM) | $-1.05 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $122.10M |
| Sales | $113.02M |
| Income | $-75.07M |
| Book/sh | $4.51 |
| Cash/sh | $2.57 |
| Employees | 500 |
Financial Ratios
| Quick Ratio | 4.61 |
| Current Ratio | 5.46 |
| Debt/Eq | 4.04 |
Returns & Margins
| ROA | -10.65% |
| ROE | -21.16% |
| Gross Margin | 42.27% |
| Operating Margin | -78.45% |
| Profit Margin | -66.42% |
Ownership
| Insider Ownership | 6.38% |
| Institutional Ownership | 88.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.27 |
| PEG | 6.19 |
| P/S | 2.53 |
| P/B | 0.92 |
Analyst Data
| Recommendation | none |
| Target Price | $4.75 |
Technical Indicators
| SMA20 | $4.12 |
| SMA50 | $3.49 |
| SMA200 | $2.98 |
| RSI | 52.07 |
| ATR | 0.2329 |
| Shares Float | 60.75M |
| Short Float | 4.34% |
| Short Ratio | 3.66 |
| Volatility | 1.01 |
| Rel Volume | 0.73 |
Performance History
| Week | -0.48% |
| Month | +35.50% |
| Quarter | +41.02% |
| 6 Months | +69.11% |
| YTD | +74.79% |
| Year | +44.44% |
| 3 Years | -23.67% |
| 5 Years | -56.26% |
| 10 Years | -38.91% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $4.16 | 621,900 |
| 2026-06-18 | $4.25 | 1,319,600 |
| 2026-06-17 | $4.47 | 744,300 |
| 2026-06-16 | $4.32 | 657,800 |
| 2026-06-15 | $4.17 | 521,700 |
| 2026-06-12 | $4.18 | 506,200 |
| 2026-06-11 | $4.19 | 776,000 |
| 2026-06-10 | $4.03 | 717,000 |
| 2026-06-09 | $4.24 | 748,300 |
| 2026-06-08 | $4.15 | 808,600 |
| 2026-06-05 | $4.04 | 554,800 |
| 2026-06-04 | $4.17 | 719,600 |
| 2026-06-03 | $3.95 | 818,300 |
| 2026-06-02 | $4.00 | 1,236,600 |
| 2026-06-01 | $4.09 | 898,700 |
| 2026-05-29 | $4.30 | 780,800 |
| 2026-05-28 | $4.23 | 1,136,400 |
| 2026-05-27 | $3.98 | 976,600 |
| 2026-05-26 | $3.94 | 1,542,500 |
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
đ° Latest News
Is Co-Diagnostics National Securityâs Next Diagnostic Pick?
MarketBeat âĸ 2026-05-28T15:00:00Z
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist
Simply Wall St. âĸ 2026-05-20T18:05:12Z
OraSure Technologies Independent Director Acquires 195% More Stock
Simply Wall St. âĸ 2026-05-17T12:21:37Z
OraSure Technologies, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T12:30:00Z
OraSure Technologies Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T03:06:38Z
OraSure (OSUR) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-06T22:47:39Z
Why OraSure Technologies (OSUR) Is Back in the Spotlight as Sale Pressure Builds
Insider Monkey âĸ 2026-04-16T07:27:27Z
OraSure Technologies, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-02-26T13:30:00Z
OraSure Technologies Q4 Earnings Call Highlights
MarketBeat âĸ 2026-02-26T07:11:24Z
OraSure Technologies Inc (OSUR) Q4 2025 Earnings Call Highlights: Revenue Exceeds Expectations ...
GuruFocus.com âĸ 2026-02-26T05:02:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $66,823,000 | $106,437,000 | $233,820,000 | $239,041,000 |
| Cost Of Revenue | $66,823,000 | $106,437,000 | $233,820,000 | $239,041,000 |
| Total Revenue | $115,021,000 | $185,827,000 | $405,472,000 | $387,479,000 |
| Operating Revenue | $109,055,000 | $184,611,000 | $402,222,000 | $378,047,000 |
| Expenses | ||||
| Total Expenses | $183,145,000 | $209,685,000 | $362,058,000 | $392,722,000 |
| Other Income Expense | $3,538,000 | $7,857,000 | $12,844,000 | $-10,432,000 |
| Other Non Operating Income Expenses | $7,383,000 | $12,249,000 | $23,574,000 | $6,481,000 |
| Operating Expense | $116,322,000 | $103,248,000 | $128,238,000 | $153,681,000 |
| Selling And Marketing Expense | $26,117,000 | $30,986,000 | $36,319,000 | $49,238,000 |
| General And Administrative Expense | $47,677,000 | $46,215,000 | $58,191,000 | $68,206,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Normalized Income | $-65,693,450 | $-16,030,320 | $63,891,420 | $-3,771,730 |
| Net Income From Continuing And Discontinued Operation | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Total Operating Income As Reported | $-71,969,000 | $-28,250,000 | $32,684,000 | $-22,156,000 |
| Net Income Common Stockholders | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Net Income | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Net Income Including Noncontrolling Interests | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Net Income Continuous Operations | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Earnings From Equity Interest Net Of Tax | $-2,344,000 | $-1,700,000 | $0 | $0 |
| Pretax Income | $-64,586,000 | $-16,001,000 | $56,258,000 | $-15,675,000 |
| Special Income Charges | $-3,845,000 | $-4,392,000 | $-10,730,000 | $-16,913,000 |
| Operating Income | $-68,124,000 | $-23,858,000 | $43,414,000 | $-5,243,000 |
| Gross Profit | $48,198,000 | $79,390,000 | $171,652,000 | $148,438,000 |
| Per Share | ||||
| Diluted EPS | $-0.94 | $-0.26 | $0.72 | $-0.25 |
| Basic EPS | $-0.94 | $-0.26 | $0.73 | $-0.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $-807,450 | $-922,320 | $-493,580 | $-3,551,730 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-54,309,000 | $-9,158,000 | $75,083,000 | $27,206,000 |
| Total Unusual Items | $-3,845,000 | $-4,392,000 | $-10,730,000 | $-16,913,000 |
| Total Unusual Items Excluding Goodwill | $-3,845,000 | $-4,392,000 | $-10,730,000 | $-16,913,000 |
| Reconciled Depreciation | $9,970,000 | $10,308,000 | $20,939,000 | $15,536,000 |
| EBITDA (Bullshit earnings) | $-58,154,000 | $-13,550,000 | $64,353,000 | $10,293,000 |
| EBIT | $-68,124,000 | $-23,858,000 | $43,414,000 | $-5,243,000 |
| Diluted Average Shares | $73,485,000 | $74,434,000 | $74,389,000 | $72,505,000 |
| Basic Average Shares | $73,485,000 | $74,434,000 | $73,348,000 | $72,505,000 |
| Diluted NI Availto Com Stockholders | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Tax Provision | $1,801,000 | $1,799,000 | $2,603,000 | $1,458,000 |
| Gain On Sale Of Ppe | $725,000 | $0 | $0 | - |
| Impairment Of Capital Assets | $0 | $4,392,000 | $10,829,000 | $17,101,000 |
| Restructuring And Mergern Acquisition | $4,570,000 | $0 | $-99,000 | $-188,000 |
| Research And Development | $42,528,000 | $26,047,000 | $33,728,000 | $36,237,000 |
| Selling General And Administration | $73,794,000 | $77,201,000 | $94,510,000 | $117,444,000 |
| Other Gand A | $47,677,000 | $46,215,000 | $58,191,000 | $68,206,000 |
| Gain On Sale Of Business | - | - | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $278,418,000 | $352,573,000 | $393,769,000 | $317,627,000 |
| Total Assets | $403,168,000 | $479,659,000 | $482,845,000 | $444,180,000 |
| Total Non Current Assets | $141,260,000 | $146,439,000 | $96,386,000 | $118,990,000 |
| Other Non Current Assets | $1,303,000 | $1,526,000 | $1,218,000 | $1,087,000 |
| Non Current Deferred Assets | $271,000 | $156,000 | $0 | - |
| Non Current Deferred Taxes Assets | $271,000 | $156,000 | $0 | - |
| Goodwill And Other Intangible Assets | $62,409,000 | $57,765,000 | $36,902,000 | $46,798,000 |
| Other Intangible Assets | $19,046,000 | $17,435,000 | $1,206,000 | $11,694,000 |
| Current Assets | $261,908,000 | $333,220,000 | $386,459,000 | $325,190,000 |
| Other Current Assets | $4,146,000 | $3,488,000 | $2,226,000 | $41,569,000 |
| Prepaid Assets | $5,221,000 | $3,956,000 | $6,041,000 | $6,273,000 |
| Inventory | $31,060,000 | $34,197,000 | $47,614,000 | $95,704,000 |
| Receivables | $22,203,000 | $23,816,000 | $40,171,000 | $70,797,000 |
| Accounts Receivable | $22,203,000 | $23,816,000 | $40,171,000 | $70,797,000 |
| Allowance For Doubtful Accounts Receivable | $-188,000 | $-774,000 | $-1,216,000 | $-2,365,000 |
| Gross Accounts Receivable | $22,391,000 | $24,590,000 | $41,387,000 | $73,162,000 |
| Cash Cash Equivalents And Short Term Investments | $199,278,000 | $267,763,000 | $290,407,000 | $110,847,000 |
| Cash And Cash Equivalents | $199,278,000 | $267,763,000 | $290,407,000 | $83,980,000 |
| Debt | ||||
| Total Debt | $13,197,000 | $14,604,000 | $13,504,000 | $12,547,000 |
| Long Term Debt And Capital Lease Obligation | $10,970,000 | $12,434,000 | $11,388,000 | $9,604,000 |
| Current Debt And Capital Lease Obligation | $2,227,000 | $2,170,000 | $2,116,000 | $2,943,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $62,341,000 | $69,321,000 | $52,174,000 | $79,755,000 |
| Total Non Current Liabilities Net Minority Interest | $22,546,000 | $35,838,000 | $12,638,000 | $10,692,000 |
| Other Non Current Liabilities | $11,576,000 | $23,404,000 | $696,000 | $680,000 |
| Current Liabilities | $39,795,000 | $33,483,000 | $39,536,000 | $69,063,000 |
| Other Current Liabilities | $21,184,000 | $5,224,000 | $3,984,000 | $5,520,000 |
| Current Deferred Liabilities | $1,518,000 | $2,961,000 | $1,559,000 | $2,273,000 |
| Payables And Accrued Expenses | $14,866,000 | $23,128,000 | $31,877,000 | $58,327,000 |
| Payables | $7,673,000 | $9,512,000 | $14,396,000 | $39,539,000 |
| Total Tax Payable | $1,152,000 | $1,339,000 | $1,245,000 | $1,519,000 |
| Accounts Payable | $6,521,000 | $8,173,000 | $13,151,000 | $38,020,000 |
| Non Current Deferred Liabilities | - | $0 | $554,000 | $408,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $554,000 | $408,000 |
| Equity | ||||
| Common Stock Equity | $340,827,000 | $410,338,000 | $430,671,000 | $364,425,000 |
| Total Equity Gross Minority Interest | $340,827,000 | $410,338,000 | $430,671,000 | $364,425,000 |
| Stockholders Equity | $340,827,000 | $410,338,000 | $430,671,000 | $364,425,000 |
| Gains Losses Not Affecting Retained Earnings | $-18,404,000 | $-24,360,000 | $-14,941,000 | $-18,435,000 |
| Other Equity Adjustments | $-18,404,000 | $-24,360,000 | $-14,941,000 | $-18,435,000 |
| Retained Earnings | $-172,162,000 | $-103,431,000 | $-83,931,000 | $-137,586,000 |
| Long Term Equity Investment | $25,956,000 | $28,300,000 | $0 | - |
| Other | ||||
| Ordinary Shares Number | $70,391,000 | $74,598,000 | $73,528,000 | $72,734,000 |
| Share Issued | $70,391,000 | $74,598,000 | $73,528,000 | $72,734,000 |
| Tangible Book Value | $278,418,000 | $352,573,000 | $393,769,000 | $317,627,000 |
| Invested Capital | $340,827,000 | $410,338,000 | $430,671,000 | $364,425,000 |
| Working Capital | $222,113,000 | $299,737,000 | $346,923,000 | $256,127,000 |
| Capital Lease Obligations | $13,197,000 | $14,604,000 | $13,504,000 | $12,547,000 |
| Total Capitalization | $340,827,000 | $410,338,000 | $430,671,000 | $364,425,000 |
| Additional Paid In Capital | $531,393,000 | $538,129,000 | $529,543,000 | $520,446,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $10,970,000 | $12,434,000 | $11,388,000 | $9,604,000 |
| Current Deferred Revenue | $1,518,000 | $2,961,000 | $1,559,000 | $2,273,000 |
| Current Capital Lease Obligation | $2,227,000 | $2,170,000 | $2,116,000 | $2,943,000 |
| Current Accrued Expenses | $7,193,000 | $13,616,000 | $17,481,000 | $18,788,000 |
| Investments And Advances | $25,956,000 | $28,300,000 | $0 | $0 |
| Goodwill | $43,363,000 | $40,330,000 | $35,696,000 | $35,104,000 |
| Net PPE | $51,321,000 | $58,692,000 | $58,266,000 | $71,105,000 |
| Accumulated Depreciation | $-62,876,000 | $-65,918,000 | $-85,143,000 | $-69,881,000 |
| Gross PPE | $114,197,000 | $124,610,000 | $143,409,000 | $140,986,000 |
| Construction In Progress | $2,931,000 | $9,615,000 | $9,196,000 | $11,124,000 |
| Other Properties | $12,142,000 | $13,587,000 | $12,846,000 | $11,692,000 |
| Machinery Furniture Equipment | $58,935,000 | $64,138,000 | $85,643,000 | $81,470,000 |
| Buildings And Improvements | $39,071,000 | $36,152,000 | $34,606,000 | $35,582,000 |
| Land And Improvements | $1,118,000 | $1,118,000 | $1,118,000 | $1,118,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $14,208,000 | $13,885,000 | $24,987,000 | $50,924,000 |
| Work In Process | $2,021,000 | $3,310,000 | $1,900,000 | $2,335,000 |
| Raw Materials | $14,831,000 | $17,002,000 | $20,727,000 | $42,445,000 |
| Other Inventories | - | $1,000 | - | - |
| Other Short Term Investments | - | - | $0 | $26,867,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-53,220,000 | $23,577,000 | $131,280,000 | $-111,111,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-49,023,000 | $27,374,000 | $141,583,000 | $-47,202,000 |
| Cash Flow From Continuing Operating Activities | $-49,023,000 | $27,374,000 | $141,583,000 | $-47,202,000 |
| Operating Gains Losses | $1,984,000 | $2,000,000 | $103,000 | $568,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,197,000 | $-3,797,000 | $-10,303,000 | $-63,909,000 |
| Investing Cash Flow | $-6,810,000 | $-39,026,000 | $66,154,000 | $21,085,000 |
| Cash Flow From Continuing Investing Activities | $-6,810,000 | $-39,026,000 | $66,154,000 | $21,085,000 |
| Net Other Investing Changes | $1,000,000 | - | $48,669,000 | $60,452,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-16,883,000 | $-3,548,000 | $-1,901,000 | $-2,254,000 |
| Financing Cash Flow | $-16,944,000 | $-4,176,000 | $-3,023,000 | $-3,828,000 |
| Cash Flow From Continuing Financing Activities | $-16,944,000 | $-4,176,000 | $-3,023,000 | $-3,828,000 |
| Net Common Stock Issuance | $-16,883,000 | $-3,548,000 | $-1,901,000 | $-2,254,000 |
| Net Other Financing Charges | - | - | $-46,000 | $-208,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-61,000 | $-842,000 | $-1,345,000 | $-1,381,000 |
| End Cash Position | $199,278,000 | $267,763,000 | $290,407,000 | $83,980,000 |
| Beginning Cash Position | $267,763,000 | $290,407,000 | $83,980,000 | $116,762,000 |
| Effect Of Exchange Rate Changes | $4,292,000 | $-6,816,000 | $1,713,000 | $-2,837,000 |
| Changes In Cash | $-72,777,000 | $-15,828,000 | $204,714,000 | $-29,945,000 |
| Proceeds From Stock Option Exercised | $0 | $214,000 | $269,000 | $15,000 |
| Common Stock Payments | $-16,883,000 | $-3,548,000 | $-1,901,000 | $-2,254,000 |
| Net Issuance Payments Of Debt | $-61,000 | $-842,000 | $-1,345,000 | $-1,381,000 |
| Net Long Term Debt Issuance | $-61,000 | $-842,000 | $-1,345,000 | $-1,381,000 |
| Long Term Debt Payments | $-61,000 | $-842,000 | $-1,345,000 | $-1,381,000 |
| Net Investment Purchase And Sale | $0 | $-192,000 | $27,788,000 | $24,542,000 |
| Sale Of Investment | $0 | $53,052,000 | $102,440,000 | $47,415,000 |
| Purchase Of Investment | $0 | $-53,244,000 | $-74,652,000 | $-22,873,000 |
| Net Business Purchase And Sale | $-3,613,000 | $-35,037,000 | $0 | $0 |
| Purchase Of Business | $-3,613,000 | $-35,037,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-4,197,000 | $-3,797,000 | $-10,303,000 | $-63,909,000 |
| Purchase Of PPE | $-4,197,000 | $-3,797,000 | $-10,303,000 | $-63,909,000 |
| Change In Working Capital | $-8,759,000 | $18,818,000 | $45,755,000 | $-72,119,000 |
| Change In Other Working Capital | $-1,519,000 | $-219,000 | $-730,000 | $-596,000 |
| Change In Payables And Accrued Expense | $-10,383,000 | $-14,020,000 | $-30,360,000 | $4,004,000 |
| Change In Accrued Expense | $-8,663,000 | $-6,443,000 | $-3,384,000 | $1,370,000 |
| Change In Payable | $-1,720,000 | $-7,577,000 | $-26,976,000 | $2,634,000 |
| Change In Account Payable | $-1,720,000 | $-7,577,000 | $-26,976,000 | $2,634,000 |
| Change In Prepaid Assets | $-2,368,000 | $4,089,000 | $-2,499,000 | $-7,091,000 |
| Change In Inventory | $3,562,000 | $13,096,000 | $48,228,000 | $-43,274,000 |
| Change In Receivables | $1,949,000 | $15,872,000 | $31,116,000 | $-25,162,000 |
| Changes In Account Receivables | $1,949,000 | $15,872,000 | $31,116,000 | $-25,162,000 |
| Other Non Cash Items | $4,578,000 | $22,000 | $-67,000 | $-94,000 |
| Stock Based Compensation | $10,147,000 | $11,920,000 | $10,729,000 | $11,622,000 |
| Provisionand Write Offof Assets | $-65,000 | $71,000 | $-462,000 | $-1,032,000 |
| Asset Impairment Charge | $0 | $4,392,000 | $10,829,000 | $17,101,000 |
| Deferred Tax | $1,853,000 | $-657,000 | $102,000 | $-1,651,000 |
| Deferred Income Tax | $1,853,000 | $-657,000 | $102,000 | $-1,651,000 |
| Depreciation Amortization Depletion | $9,970,000 | $10,308,000 | $20,939,000 | $15,536,000 |
| Depreciation And Amortization | $9,970,000 | $10,308,000 | $20,939,000 | $15,536,000 |
| Amortization Cash Flow | $-222,000 | $-564,000 | $3,000 | $228,000 |
| Amortization Of Intangibles | $-222,000 | $-564,000 | $3,000 | $228,000 |
| Depreciation | $10,192,000 | $10,872,000 | $20,936,000 | $15,308,000 |
| Earnings Losses From Equity Investments | $2,344,000 | $1,700,000 | $0 | $0 |
| Net Foreign Currency Exchange Gain Loss | $365,000 | $-263,000 | $103,000 | $-161,000 |
| Gain Loss On Sale Of PPE | $-725,000 | $563,000 | $0 | $729,000 |
| Net Income From Continuing Operations | $-68,731,000 | $-19,500,000 | $53,655,000 | $-17,133,000 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Gain Loss On Sale Of Business | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Sale Of Business | - | - | - | - |
Fetched: 2026-06-23